CCR Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The NCI Center for Cancer Research (CCR) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 33 clinical trials at NIH that match your search criteria

Cancer by type/disease: Solid Tumor

Trial and Protocol Number Solid Tumor	Principal Investigator	Referral Contact
Phase II
A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors NCI-09-C-0138	Shivaani Kummar 301-435-5402	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
Phase II Study of Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) Using Lymphodepleting Conditioning Followed by Infusion of Anti-CEA TCR-Gene Engineered Lymphocytes NCI-09-C-0047	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes NCI-08-C-0121	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
A Phase II Study of Hypofractionated Highly Conformal Radiation With Helical Tomotherapy for Extra-Cranial Oligometastases NCI-07-C-0230	Deborah Citrin 301-496-5457	Sharon L. Smith 301-496-5457 smiths@mail.nih.gov
Phase I
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers NCI-09-C-0173	Richard Piekarz 301-496-1196	Robin Frye 301-402-5958 fryer@mail.nih.gov
A Phase I, Open-Label Study of MEDI-547 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biologic Activity of Intravenous Administration in Subjects With Refractory Solid Tumors Associated With EphA2 Expression NCI-09-C-0168	Elise C. Kohn 301-402-2726	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase I, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies NCI-09-C-0111	Susan Bates 301-402-1357	Debbie Draper 301-435-8525 draperde@mail.nih.gov
An Open-Label Phase I Study to Evaluate the Safety and Tolerability of a Vaccine Consisting of Whole, Heat-Killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing Carcinoma NCI-09-C-0101	James L. Gulley 301-435-2956	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Targeted Phase I Trial of ZD6474 (Vandetanib; ZACTIMA^®) Plus the Proteasome Inhibitor Bortezomib (Velcade^®) in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) NCI-09-C-0089	Antonio Tito Fojo 301-402-1357	Maureen Edgerly 301-435-5604 edgerlym@mail.nih.gov
A Phase I Study of ABT-888 in Combination With Metronomic Cyclophosphamide in Adults With Refractory Solid Tumors and Lymphomas NCI-09-C-0048	Shivaani Kummar 301-435-5402	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors NCI-09-C-0019	Elise C. Kohn 301-402-2726	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase I and Pharmacokinetic Single-Agent Study of Pazopanib in Adults With Advanced Malignancies and Varying Degrees of Liver Dysfunction NCI-09-C-0003	Shivaani Kummar 301-435-5402	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase I Study of VEGF Trap (NSC #724770, IND #100137) in Children With Refractory Solid Tumors (Children’s Oncology Group Study ADVL0714) NCI-08-C-0179	Elizabeth Fox 301-402-6641	Pediatric Oncology 1-877-624-4878 (Toll free)
A Phase I Combination Study of AZD2281 and Cisplatin Plus Gemcitabine in Adults With Solid Tumors NCI-08-C-0128	Giuseppe Giaccone 301-496-4916	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
Phase I Study of SNX-5422 Mesylate in Adults With Refractory Solid Tumor Malignancies and Lymphomas NCI-08-C-0091	Giuseppe Giaccone 301-496-4916	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
Phase I Trial of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb^TM (LXS) Oral Powder (4-HPR/LXS Oral Powder) (4-HPR) in Adults With Solid Tumors and Lymphomas NCI-08-C-0030	Shivaani Kummar 301-435-5402	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults With Treatment Refractory Cancer NCI-08-C-0007	Crystal Mackall 301-402-5940	Pediatric Oncology 1-877-624-4878 (Toll free)
A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children With Refractory Solid Tumors NCI-07-C-0220 (A Cooperative Group Study: ADVL0612)	Elizabeth Fox 301-402-6641	Pediatric Oncology 1-877-624-4878 (Toll free)
A Phase I Study of BMS-354825 (Dasatinib) in Children With Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia (A Cooperative Group Study) NCI-07-C-0166	Elizabeth Fox 301-402-6641	Pediatric Oncology 1-877-624-4878 (Toll free)
A Phase I Study of Batracylin (NSC320846) in Subjects With Solid Tumors and Lymphomas NCI-07-C-0097	Shivaani Kummar 301-435-5402	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Phase I Trial and Pharmacokinetic Study of Trabectedin (YONDELIS^®, ET-743) in Children and Adolescents With Relapsed or Refractory Solid Tumors NCI-07-C-0054	Elizabeth Fox 301-402-6641	Pediatric Oncology 1-877-624-4878 (Toll free)
A Phase I Trial of Nelfinavir (Viracept^®) in Adults With Solid Tumors NCI-07-C-0047	Phillip A. Dennis 301-496-0929	Hyejeong Root 301-402-0998 roothy@mail.nih.gov
Phase I Trial of Monoclonal Antibody HGS-ETR2 (Lexatumumab) in Patients With Refractory Pediatric Solid Tumors NCI-07-C-0040	Crystal Mackall 301-402-5940	Pediatric Oncology 1-877-624-4878 (Toll free)
A Phase I Trial of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies NCI-06-C-0221	James Doroshow 301-496-4291	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1 Alpha NCI-05-C-0186	Shivaani Kummar 301-435-5402	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Phase I Investigation of IL-12/Pulse IL-2 in Adults With Advanced Solid Tumors NCI-00-C-0121	John E. Janik 301-402-2913	Debbie Draper 301-435-8525 draperde@mail.nih.gov
Phase 0
A Phase 0 Trial of [111] Indium CHX-A" DTPA Trastuzumab Imaging in Cancer NCI-07-C-0101	Peter Choyke 301-451-4220	Yolanda McKinney 301-443-6913 ymckinney@mail.nih.gov
No Phase
A Natural History Study of Patients Receiving High Dose Rate Brachytherapy NCI-09-C-0100	Aradhana Kaushal 301-496-5457	Sharon L. Smith 301-496-5457 smiths@mail.nih.gov
The Natural History of Solid Organ Cancer Stem Cells NCI-09-C-0079	Itzhak Avital 301-402-0083	Melissa Walker 301-402-9537 walkerme@mail.nih.gov
A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies NCI-07-C-0111	Deborah Citrin 301-496-5457	Sharon L. Smith 301-496-5457 smiths@mail.nih.gov
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease NCI-97-C-0147	W. Marston Linehan 301-496-6353

Trial and Protocol Number Pediatric Cancers	Principal Investigator	Referral Contact
Phase I
A Phase I Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor BAY 43-9006 (Sorafenib) in Children With Refractory Solid Tumors or Refractory Leukemias NCI-06-C-0233	Brigitte Widemann 301-496-7387	Pediatric Oncology 1-877-624-4878 (Toll free)
Phase I Trial of Cediranib (AZ2171), an Orally Bioavailable Antiangiogenic Agent, in Children and Adolescents With Refractory or Recurrent Solid Tumors or Acute Myelogenous Leukemia NCI-06-C-0152	Elizabeth Fox 301-402-6641	Pediatric Oncology 1-877-624-4878 (Toll free)

For additional studies that may be appropriate for your disease type, please search under Solid Tumor.